CorMedix (CRMD) CFO Susan Blum gets 72,820 RSUs and withholds shares for taxes

Rhea-AI Filing Summary

CorMedix Inc. Chief Financial Officer Susan Blum reported equity compensation and related share withholding transactions. On 01/23/2026, she was granted 72,820 restricted stock units, each representing one share of CorMedix common stock at a stated price of $0.00.

The restricted stock units vest 1/4 on the grant date and, subject to continued employment, 1/4 on each of the first, second, and third anniversaries of the grant. On the same date, 9,767 shares of common stock were disposed of at $7.27 per share in a transaction coded "F," typically indicating shares withheld to cover taxes. After these transactions, Blum directly owned 132,739 shares of CorMedix common stock.

Insights

Equity Compensation Analyst

CFO receives time-based RSU grant with tax-share withholding.

The filing shows Susan Blum, Chief Financial Officer of CorMedix Inc., receiving 72,820 restricted stock units on 01/23/2026 at a stated price of $0.00. Each unit represents one share of common stock subject to a multi-year vesting schedule.

The units vest 1/4 at grant and 1/4 on each of the first three anniversaries, conditioned on continued employment. A separate transaction coded "F" disposes of 9,767 shares at $7.27 per share, which is commonly used for tax withholding on equity awards.

After these transactions, Blum directly holds 132,739 common shares, aligning her compensation partly with equity performance. The filing does not indicate unusual structures or derivative positions; subsequent company filings will provide further context on any future vesting or additional grants.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Blum Susan

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	72,820	$0.00	--
Tax Withholding	Common Stock	9,767	$7.27	$71K

Holdings After Transaction: Common Stock — 142,506 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Blum Susan

(Last) (First) (Middle)

C/O CORMEDIX INC.,

389 INTERPACE PKWY, SUITE 450

(Street)

PARSIPPANY NJ 07054

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CorMedix Inc. [ CRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/23/2026		A		72,820	A	$0.00(1)	142,506	D
Common Stock	01/23/2026		F		9,767	D	$7.27	132,739	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares represent restricted stock units granted on 01/23/2026. Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. These restricted stock units vest 1/4 on the date of grant, and, subject to continued employment, 1/4 on the first anniversary of the date of grant, 1/4 on the second anniversary of the date of grant and 1/4 on the third anniversary of the date of grant.

Remarks:

Exhibit 24.1 - Power of Attorney

	/s/ Beth Zelnick Kaufman, attorney-in-fact	01/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity award did CorMedix (CRMD) CFO Susan Blum receive on 01/23/2026?

Susan Blum received 72,820 restricted stock units on 01/23/2026. Each RSU represents one share of CorMedix common stock at a stated price of $0.00, forming part of her equity-based compensation tied to the company’s stock.

How do Susan Blum’s 2026 CorMedix (CRMD) RSUs vest over time?

The 72,820 restricted stock units vest in four equal parts. One-quarter vests on the grant date, and, subject to continued employment, one-quarter vests on each of the first, second, and third anniversaries of the 01/23/2026 grant date.

What does the Form 4 transaction code "A" mean for CorMedix (CRMD) CFO Susan Blum?

Transaction code "A" on Susan Blum’s Form 4 indicates an acquisition of securities, here 72,820 restricted stock units. These units are part of her compensation package and convert to common shares as they vest over the specified four-year schedule.

Why did CorMedix (CRMD) CFO Susan Blum dispose of 9,767 shares at $7.27?

Susan Blum reported a transaction coded "F" disposing of 9,767 shares at $7.27 per share. Code "F" typically reflects shares withheld by the issuer to satisfy tax obligations arising from the vesting or settlement of equity awards such as restricted stock units.

How many CorMedix (CRMD) shares does CFO Susan Blum own after these transactions?

After the reported Form 4 transactions, Susan Blum directly owns 132,739 shares of CorMedix common stock. This figure reflects the RSU-related activity and the 9,767-share tax withholding transaction reported for 01/23/2026.

Does the CorMedix (CRMD) Form 4 show any derivative securities for Susan Blum?

The filing’s derivative securities table contains no entries for Susan Blum. Her reported activity relates only to non-derivative common stock and restricted stock units, with no options, warrants, or other derivative instruments listed in this particular Form 4.